NASDAQ:CMPS Compass Pathways Q4 2025 Earnings Results & Report $11.29 +0.02 (+0.19%) As of 01:59 PM Eastern This is a fair market value price provided by Massive. Learn more. Compass Pathways missed analyst earnings expectations in its Q4 2025 results, released March 24, 2026. The company reported EPS of -$1.00 versus the -$0.41 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ4 2025Report DateMarch 24, 2026TimeBefore Market OpensConference Call7:00 AM ET Compass Pathways EPS ResultsActual EPS-$1.00Consensus EPS -$0.41Beat/MissMissed by -$0.59One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersCompass Pathways Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsCompass Pathways' Q3 2026 earnings is estimated for Tuesday, November 3, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 5, 2026 at 2:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (6-K)Annual Report (10-K)Annual ReportSEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Annual report(10-K)Annual report Compass Pathways Q4 2025 Earnings FAQ Did Compass Pathways beat earnings estimates for Q4 2025? Compass Pathways (NASDAQ:CMPS) reported earnings of -$1.00 per share for Q4 2025, missing the consensus estimate of -$0.41. The report was announced on Tuesday, March 24, 2026. When is Compass Pathways' next earnings date? Compass Pathways' next earnings date is estimated for Tuesday, November 3, 2026. MarketBeat tracks confirmed and estimated earnings dates for Compass Pathways on the company's earnings history page. Compass Pathways Earnings HeadlinesCompass Pathways Announces New Employee Inducement Grants under Nasdaq Listing Rule 5635(4)October 5, 2026 | marketscreener.comMCompass Pathways : Celebrates Opening of New U.S. Office in Jersey City, New JerseyOctober 5, 2026 | marketscreener.comMTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.October 15 at 1:00 AM | Banyan Hill Publishing (Ad)Compass Pathfinder Limited: Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | finanznachrichten.deCompass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | businesswire.comCOMPASS Pathways (CMPS) Could Be 49% Below Fair Value Following Its Phase III ProgressOctober 1, 2026 | finance.yahoo.comSee More Compass Pathways Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Compass Pathways? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Compass Pathways and other key companies, straight to your email. Email Address About Compass PathwaysCompass Pathways (NASDAQ:CMPS) plc is a biotechnology company developing psychedelic treatments for mental health conditions. The company’s lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting. Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not achieve adequate relief from standard therapies. Its research has also explored the potential use of COMP360 in other serious mental health disorders. COMP360 is an investigational therapy and has not been approved for commercial use by regulatory authorities. Founded in 2016, Compass Pathways is headquartered in London and has conducted clinical development activities in the United States, the United Kingdom and other European countries. The company’s leadership includes Chief Executive Officer Kabir Nath, who joined Compass Pathways after holding senior positions in the biopharmaceutical industry.View Compass Pathways ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple Cut iPhone 18 Orders; What Does It Mean For Suppliers?Domino’s Pizza: As Cheap As It Gets, Nowhere to Go But UpFastenal Flashes Bullish Signal as Uptrend Holds Despite Margin PressureCiti Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenBig Banks Report Strong Earnings—So Why Are Shares Falling?UnitedHealth Beats on Earnings, But Investors Question Growth Path Upcoming Earnings Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026)ICICI Bank (10/17/2026)America Movil (10/20/2026)Netflix (10/20/2026)General Motors (10/20/2026)Chubb (10/20/2026)Capital One Financial (10/20/2026)Intuitive Surgical (10/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
